Protective Effects of Silymarin in Glioblastoma Cancer Cells Through Redox System Regulation

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2024 Jun 4

PMID 38833199

Authors

Sara Zarei Shandiz

Bahareh Erfani

Seyed Isaac Hashemy

Affiliations

Soon will be listed here.

Abstract

Background: Glioblastoma multiforme, a deadly form of brain tumor, is characterized by aggressive growth and poor prognosis. Oxidative stress, a disruption in the balance between antioxidants and oxidants, is a crucial factor in its pathogenesis. Silymarin, a flavonoid extracted from milk thistle, has shown therapeutic potential in inhibiting cancer cell growth, promoting apoptosis, and reducing inflammation. It also regulates oxidative stress. This study aims to investigate the regulatory effects of silymarin on oxidative stress parameters, especially the transcription factor Nrf2 and its related enzymes in GBM cancer cells, to develop a new anti-cancer compound with low toxicity.

Methods And Results: First, the cytotoxicity of silymarin on U-87 MG cells was investigated by MTT and the results showed an IC50 of 264.6 μM. Then, some parameters of the redox system were measured with commercial kits, and the obtained results showed that silymarin increased the activity of catalase and superoxide dismutase enzymes, as well as the total antioxidant capacity levels; while the malondialdehyde level that is an indicator of lipid peroxidation was decreased by this compound. The expression level of Nrf2 and HO-1 and glutaredoxin and thioredoxin enzymes were checked by real-time PCR method, and the expression level increased significantly after treatment.

Conclusions: Our findings suggest that silymarin may exert its cytotoxic and anticancer effects by enhancing the Nrf2/HO-1 pathway through antioxidant mechanisms in U-87 MG cells.

Citing Articles

The interplay of exercise and green tea: a new road in cancer therapy.

Liu B, Tian H, Momeni M Cancer Cell Int. 2025; 25(1):6.

PMID: 39773739 PMC: 11705833. DOI: 10.1186/s12935-024-03632-7.

References

Grochans S, Cybulska A, Siminska D, Korbecki J, Kojder K, Chlubek D . Epidemiology of Glioblastoma Multiforme-Literature Review. Cancers (Basel). 2022; 14(10). PMC: 9139611. DOI: 10.3390/cancers14102412. View

Ghahremani F, Sabbaghzadeh R, Ebrahimi S, Javid H, Ghahremani J, Hashemy S . Pathogenic role of the SP/ NK1R system in GBM cells through inhibiting the thioredoxin system. Iran J Basic Med Sci. 2021; 24(4):499-505. PMC: 8143719. DOI: 10.22038/ijbms.2021.52902.11945. View

Salazar-Ramiro A, Ramirez-Ortega D, la Cruz V, Hernandez-Pedro N, Gonzalez-Esquivel D, Sotelo J . Role of Redox Status in Development of Glioblastoma. Front Immunol. 2016; 7:156. PMC: 4844613. DOI: 10.3389/fimmu.2016.00156. View

Waris G, Ahsan H . Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog. 2006; 5:14. PMC: 1479806. DOI: 10.1186/1477-3163-5-14. View

Rao G, Rao A, Raja A, Rao S, Rao A . Role of antioxidant enzymes in brain tumours. Clin Chim Acta. 2000; 296(1-2):203-12. DOI: 10.1016/s0009-8981(00)00219-9. View

Godoy P, Pour Khavari A, Rizzo M, Sakamoto-Hojo E, Haghdoost S . Targeting NRF2, Regulator of Antioxidant System, to Sensitize Glioblastoma Neurosphere Cells to Radiation-Induced Oxidative Stress. Oxid Med Cell Longev. 2020; 2020:2534643. PMC: 7315280. DOI: 10.1155/2020/2534643. View

Karimi G, Vahabzadeh M, Lari P, Rashedinia M, Moshiri M . "Silymarin", a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci. 2013; 14(4):308-17. PMC: 3586829. View

Toklu H, Tunali-Akbay T, Erkanli G, Yuksel M, Ercan F, Sener G . Silymarin, the antioxidant component of Silybum marianum, protects against burn-induced oxidative skin injury. Burns. 2007; 33(7):908-16. DOI: 10.1016/j.burns.2006.10.407. View

Vargas-Mendoza N, Morales-Gonzalez A, Morales-Martinez M, Soriano-Ursua M, Delgado-Olivares L, Sandoval-Gallegos E . Flavolignans from Silymarin as Nrf2 Bioactivators and Their Therapeutic Applications. Biomedicines. 2020; 8(5). PMC: 7277158. DOI: 10.3390/biomedicines8050122. View

10.

Hosseinabadi T, Lorigooini Z, Tabarzad M, Salehi B, Rodrigues C, Martins N . Silymarin antiproliferative and apoptotic effects: Insights into its clinical impact in various types of cancer. Phytother Res. 2019; 33(11):2849-2861. DOI: 10.1002/ptr.6470. View

11.

Li L, Sun H, Liu W, Zhao H, Shao M . Silymarin protects against acrylamide-induced neurotoxicity via Nrf2 signalling in PC12 cells. Food Chem Toxicol. 2017; 102:93-101. DOI: 10.1016/j.fct.2017.01.021. View

12.

Hanif F, Muzaffar K, Perveen K, Malhi S, Simjee S . Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. Asian Pac J Cancer Prev. 2017; 18(1):3-9. PMC: 5563115. DOI: 10.22034/APJCP.2017.18.1.3. View

13.

Ohka F, Natsume A, Wakabayashi T . Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int. 2012; 2012:878425. PMC: 3317017. DOI: 10.1155/2012/878425. View

14.

Yao M, Li S, Wu X, Diao S, Zhang G, He H . Cellular origin of glioblastoma and its implication in precision therapy. Cell Mol Immunol. 2018; 15(8):737-739. PMC: 6141605. DOI: 10.1038/cmi.2017.159. View

15.

Bai Z, Tay V, Guo S, Ren J, Shu M . Silibinin Induced Human Glioblastoma Cell Apoptosis Concomitant with Autophagy through Simultaneous Inhibition of mTOR and YAP. Biomed Res Int. 2018; 2018:6165192. PMC: 5892302. DOI: 10.1155/2018/6165192. View

16.

Chakrabarti M, Ray S . Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo. Apoptosis. 2015; 21(3):312-28. DOI: 10.1007/s10495-015-1198-x. View

17.

Czarnik-Kwasniak J, Kwasniak K, Kwasek P, Swierzowska E, Strojewska A, Tabarkiewicz J . The Influence of Lycopene, [6]-Gingerol, and Silymarin on the Apoptosis on U-118MG Glioblastoma Cells In Vitro Model. Nutrients. 2020; 12(1). PMC: 7019537. DOI: 10.3390/nu12010096. View

18.

Zaki Dizaji M, Malehmir M, Ghavamzadeh A, Alimoghaddam K, Ghaffari S . Synergistic effects of arsenic trioxide and silibinin on apoptosis and invasion in human glioblastoma U87MG cell line. Neurochem Res. 2011; 37(2):370-80. DOI: 10.1007/s11064-011-0620-1. View

19.

Ramakrishnan G, Lo Muzio L, Elinos-Baez C, Jagan S, Augustine T, Kamaraj S . Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells. Cell Prolif. 2009; 42(2):229-40. PMC: 6495958. DOI: 10.1111/j.1365-2184.2008.00581.x. View

20.

Koltai T, Fliegel L . Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions. J Evid Based Integr Med. 2022; 27:2515690X211068826. PMC: 8814827. DOI: 10.1177/2515690X211068826. View